Table 1. Baseline Demographic and Disease Characteristics.
| Characteristic | Patients, No. (%) | |
|---|---|---|
| Paclitaxel, cisplatin, and capecitabine (n = 118) | Cisplatin and fluorouracil (n = 120) | |
| Age, median (IQR), y | 45.5 (36.2-52.8) | 46.0 (39.0-52.0) |
| Sex | ||
| Female | 29 (24.6) | 22 (18.3) |
| Male | 89 (75.4) | 98 (81.7) |
| ECOG performance status | ||
| 0 | 101 (85.6) | 105 (87.5) |
| 1 | 17 (14.4) | 15 (12.5) |
| Tumor category | ||
| T1 | 1 (0.8) | 4 (3.3) |
| T2 | 5 (4.2) | 2 (1.7) |
| T3 | 34 (28.8) | 32 (26.7) |
| T4 | 78 (66.1) | 82 (68.3) |
| Node category | ||
| N0 | 4 (3.4) | 5 (4.2) |
| N1 | 26 (22.0) | 21 (17.5) |
| N2 | 34 (28.8) | 37 (30.8) |
| N3 | 54 (45.8) | 57 (47.5) |
| Disease stage | ||
| IVA | 64 (54.2) | 63 (52.5) |
| IVB | 54 (45.8) | 57 (47.5) |
| EBV DNA, copies/mL | ||
| Median (IQR) | 1340 (335-6915) | 1950 (319-12 400) |
| Missing | 0 | 1 (0.8) |
Abbreviations: EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group.